Loading...
•
Jun 30
scPharmaceuticals Q2 2025 Earnings Report
scPharmaceuticals reported second quarter 2025 financial results, with significant revenue growth for FUROSCIX and progress in expanding its market reach and product development.
Key Takeaways
scPharmaceuticals demonstrated strong performance in Q2 2025, driven by a 99% increase in FUROSCIX net revenue to $16 million. The company also saw a substantial rise in doses filled and expanded into the chronic kidney disease market, while maintaining a solid cash position.
Net FUROSCIX revenue reached $16 million in Q2 2025, marking a 99% increase compared to Q2 2024.
Approximately 20,200 FUROSCIX doses were filled, representing a 117% annual growth.
The company formally launched FUROSCIX for the treatment of edema in patients with chronic kidney disease (CKD) in late April 2025.
Cash and cash equivalents stood at $40.8 million as of June 30, 2025.
scPharmaceuticals
scPharmaceuticals
scPharmaceuticals Revenue by Segment
Revenue by Segment
FUROSCIX Revenue
CapyFin.com Forward Guidance
scPharmaceuticals is focused on expanding the market for FUROSCIX, particularly with the new CKD indication, and advancing the development of the autoinjector to enhance patient convenience and reduce administration time.
Positive Outlook
- Formal launch of FUROSCIX for the treatment of edema in patients with chronic kidney disease (CKD) in late April 2025, with prescriptions already being written by nephrologists.
- The 80mg/1mL FUROSCIX Autoinjector (SCP-111 program) is on track for a targeted sNDA filing in Q3 2025, aiming to reduce administration time significantly.
- The proposed Ambulatory Specialty Model (ASM) by CMS for 2026 is expected to be a tailwind for FUROSCIX uptake by shifting accountability to clinical specialists for unplanned heart failure hospitalizations.
- Continued strong execution and increasing adoption by prescribers recognizing the clinical and economic value of FUROSCIX.
- Increased sales to Integrated Delivery Networks, up 70% in Q2 2025 compared to Q1 2025.
Challenges Ahead
- The company continues to incur significant operating losses and expects this trend to continue.
- There is a risk that the company may need additional funding and may be unable to raise capital when needed.
- Clinical and preclinical development processes are lengthy and expensive with uncertain outcomes.
- Regulatory approval for product candidates, including the autoinjector, is not guaranteed.
- Global economic factors and uncertainties could impact the company's operations.